IP Library Granted Patent US 10,829,470
Granted Patent B2
US 10,829,470 · App. 15/941,433 · Granted Nov 10, 2020

Compounds and uses thereof for the modulation of hemoglobin

Inventors: Brian W. Metcalf (South San Francisco, CA); Zhe Li (San Diego, CA); Qing Xu (South San Francisco, CA); Stephen L. Gwaltney, II (South San Francisco, CA); Jason R. Harris (South San Francisco, CA); Calvin W. Yee (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D401/04A61K8/4913A61K31/445A61K31/5375C07C65/30C07D211/62C07D211/70C07D213/30C07D213/64C07D213/69C07D227/08C07D231/56C07D257/04C07D401/12C07D401/14C07D405/04C07D405/14C07D471/04C07D487/04C07F7/0812
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,470
App. No.
15/941,433
Granted
Nov 10, 2020
Kind
B2
Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Claims (17)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is suitable for oral delivery.

9. A method for treating sickle cell disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 8 .

10. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a compound of claim 1 or a pharmaceutically acceptable salt thereof.

11. A method for treating sickle cell disease comprising administering to a subject in need thereof a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2019
From: METCALF, BRIAN W.; LI, ZHE; XU, QING; GWALTNEY, STEPHEN L., II; HARRIS, JASON R.; YEE, CALVIN W.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 049646/0864 →
Continuity (5)
Continuation 14776603
Continuation In Part 13815770 · Mar 15, 2013
Provisional Application 61905802 · Nov 18, 2013
Provisional Application 61905803 · Nov 18, 2013
Related Publication 20190112287A1 · Apr 18, 2019